+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease



Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease



Antiviral Research 92(2): 204-212



SARS coronavirus main protease (SARS-CoV M(pro)) is essential for the replication of the virus and regarded as a major antiviral drug target. The enzyme is a cysteine protease, with a catalytic dyad (Cys-145/His-41) in the active site. Aldehyde inhibitors can bind reversibly to the active-site sulfhydryl of SARS-CoV M(pro). Previous studies using peptidic substrates and inhibitors showed that the substrate specificity of SARS-CoV M(pro) requires glutamine in the P1 position and a large hydrophobic residue in the P2 position. We determined four crystal structures of SARS-CoV M(pro) in complex with pentapeptide aldehydes (Ac-ESTLQ-H, Ac-NSFSQ-H, Ac-DSFDQ-H, and Ac-NSTSQ-H). Kinetic data showed that all of these aldehydes exhibit inhibitory activity towards SARS-CoV M(pro), with K(i) values in the μM range. Surprisingly, the X-ray structures revealed that the hydrophobic S2 pocket of the enzyme can accommodate serine and even aspartic-acid side-chains in the P2 positions of the inhibitors. Consequently, we reassessed the substrate specificity of the enzyme by testing the cleavage of 20 different tetradecapeptide substrates with varying amino-acid residues in the P2 position. The cleavage efficiency for the substrate with serine in the P2 position was 160-times lower than that for the original substrate (P2=Leu); furthermore, the substrate with aspartic acid in the P2 position was not cleaved at all. We also determined a crystal structure of SARS-CoV M(pro) in complex with aldehyde Cm-FF-H, which has its P1-phenylalanine residue bound to the relatively hydrophilic S1 pocket of the enzyme and yet exhibits a high inhibitory activity against SARS-CoV M(pro), with K(i)=2.24±0.58 μM. These results show that the stringent substrate specificity of the SARS-CoV M(pro) with respect to the P1 and P2 positions can be overruled by the highly electrophilic character of the aldehyde warhead, thereby constituting a deviation from the dogma that peptidic inhibitors need to correspond to the observed cleavage specificity of the target protease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036175823

Download citation: RISBibTeXText

PMID: 21854807

DOI: 10.1016/j.antiviral.2011.08.001


Related references

An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. Chembiochem 7(7): 1048-1055, 2006

Substrate specificity and rational design of peptidomimetic inhibitors for SARS coronavirus main protease. Hong Kong Medical Journal 20(Suppl. 4): 18-21, 2014

Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Protein Science 15(4): 699-709, 2006

Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease. Biophysical Journal 98(7): 1327-1336, 2010

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43(17): 4906-4912, 2004

Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry 46(30): 8744-8752, 2007

Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. Journal of Molecular Biology 353(5): 1137-1151, 2005

Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase. Journal of Molecular Biology 366(3): 916-932, 2007

Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant. Bioorganic and Medicinal Chemistry 16(21): 9400-9408, 2008

Characterization and inhibition of SARS-coronavirus main protease. Current Topics in Medicinal Chemistry 6(4): 361-376, 2006

Characterization and Inhibition of Sars-Coronavirus Main Protease. Current Topics in Medicinal Chemistry 6(4): 361-376, 2006

The substrate specificity of SARS coronavirus 3C-like proteinase. Biochemical and Biophysical Research Communications 329(3): 934-940, 2005

Mechanism for controlling the monomer-dimer conversion of SARS coronavirus main protease. Acta Crystallographica. Section D Biological Crystallography 69(Pt 5): 747-755, 2013

Inhibitor Design for Sars Coronavirus Main Protease Based on Distorted Key Theory. Medicinal Chemistry 3(1): 1-6, 2007

Inhibitor design for SARS coronavirus main protease based on "distorted key theory". Medicinal Chemistry ) 3(1): 1-6, 2007